Literature DB >> 35614149

Clinical features, predictors and outcome of posterior reversible encephalopathy syndrome (PRES) in children with hematolymphoid malignancies.

Subramaniam Ramanathan1, Vignesh Subramani1, Seema Kembhavi2, Maya Prasad1, Nirmalya Roy Moulik1, Chetan Dhamne3, Gaurav Narula1, Shripad Banavali1.   

Abstract

BACKGROUND AND AIM: Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological syndrome characterized by a neurotoxic state with vasogenic edema. We studied the clinical profile, predisposing factors, imaging features, and outcome of PRES in children receiving treatment for hematolymphoid malignancies.
METHODS: Retrospective analysis of the clinical data and radiological features of patients with PRES diagnosed between June 2014 and December 2019.
RESULTS: Fifty-two patients (boy: girl = 3:1) were diagnosed with PRES during the study period with a median age of 11 (range:1-15) years. Primary diagnoses were acute leukemias (n = 42), non-Hodgkin lymphoma (n = 8), Hodgkin lymphoma (n = 1), and Langerhan's cell histiocytosis (n = 1). Most common presenting symptoms were seizures (n = 52), altered sensorium (n = 42), headache (n = 39), and visual disturbances (n = 8). Hypertension at time of diagnosis was noted in 50 (96%) patients. Classic hyper-intense lesions on FLAIR and diffusion weighed (DW) images were noted in parieto-occipital region in 39 patients (75%). Central PRES involving basal ganglia was seen in 3 (6%) patients. A subsequent neuro-imaging was done in 18 patients (MRI: 13; CT: 5) at a median interval of 16.2 weeks. Neurological sequelae were observed in 10 (19%) patients, whereas 1 succumbed due to PRES.
CONCLUSIONS: PRES is an important clinico-radiological syndrome in patients undergoing chemotherapy for hematological malignancies. High index of suspicion, early diffusion-weighted images on MRI in children with classic symptoms help in early diagnosis. A small minority of patients may develop long-term sequelae.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Childhood cancer; Magnetic resonance imaging (MRI); Posterior reversible encephalopathy syndrome (PRES); Seizures

Mesh:

Year:  2022        PMID: 35614149     DOI: 10.1007/s00381-022-05557-w

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.532


  24 in total

1.  Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions.

Authors:  S O Casey; R C Sampaio; E Michel; C L Truwit
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

2.  Transient posterior encephalopathy induced by chemotherapy in children.

Authors:  R Sánchez-Carpintero; J Narbona; R López de Mesa; J Arbizu; L Sierrasesúmaga
Journal:  Pediatr Neurol       Date:  2001-02       Impact factor: 3.372

Review 3.  Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions.

Authors:  Jennifer E Fugate; Alejandro A Rabinstein
Journal:  Lancet Neurol       Date:  2015-07-13       Impact factor: 44.182

4.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

5.  Blood pressure distribution in Indian children.

Authors:  Manu Raj; Ramaiyer Sundaram; Mary Paul; Krishna Kumar
Journal:  Indian Pediatr       Date:  2010-06       Impact factor: 1.411

Review 6.  Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.

Authors:  Kjeld Schmiegelow; Andishe Attarbaschi; Shlomit Barzilai; Gabriele Escherich; Thomas Leth Frandsen; Christina Halsey; Rachael Hough; Sima Jeha; Motohiro Kato; Der-Cherng Liang; Torben Stamm Mikkelsen; Anja Möricke; Riitta Niinimäki; Caroline Piette; Maria Caterina Putti; Elizabeth Raetz; Lewis B Silverman; Roderick Skinner; Ruta Tuckuviene; Inge van der Sluis; Ester Zapotocka
Journal:  Lancet Oncol       Date:  2016-06       Impact factor: 41.316

7.  Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies.

Authors:  C S Tam; J Galanos; J F Seymour; A G Pitman; R J Stark; H M Prince
Journal:  Am J Hematol       Date:  2004-09       Impact factor: 10.047

8.  Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.

Authors:  Brian H Kushner; Shakeel Modak; Ellen M Basu; Stephen S Roberts; Kim Kramer; Nai-Kong V Cheung
Journal:  Cancer       Date:  2013-04-30       Impact factor: 6.860

9.  Clinical spectrum of reversible posterior leukoencephalopathy syndrome.

Authors:  Vivien H Lee; Eelco F M Wijdicks; Edward M Manno; Alejandro A Rabinstein
Journal:  Arch Neurol       Date:  2008-02

10.  Clinical and radiological spectrum of posterior reversible encephalopathy syndrome: does age make a difference?--A retrospective comparison between adult and pediatric patients.

Authors:  Eberhard Siebert; Georg Bohner; Matthias Endres; Thomas G Liman
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.